THE CLINICAL RESULTS DESKA result needs
its question.
Three original-source study summaries. Compare arms inside a trial—not percentages across different populations, endpoints or estimands.
Research edition · 29 October 2026. These are selected evidence summaries, not a comprehensive trial census or treatment recommendations. Trial doses identify study arms, not prescribing instructions. Full papers, supplements and qualified clinical review remain outstanding. Investigational status is attributed to the reviewed records, not inferred from study registration or a publication.
01 PopulationWho was studied?→02 ComparatorAgainst what?→03 EstimandWhich treatment effect?→04 SafetyWhat is still missing?
Peer-reviewed abstract / 2026-09-29TRIUMPH-1
Adults with obesity without diabetes
Randomized, double-blind, placebo-controlled; 2,339 randomized; 80 weeks
- Endpoint
- Mean body-weight change
- Estimand
- Treatment-regimen / ITT
Investigational in reviewed sources. Full paper and supplementary safety tables not reviewed.
Read the full analysis ↗ WITHIN-TRIAL VIEW / %
Bars show magnitude of reduction; zero at left, 30 % at right. Values retain their negative change signs.
Original source ↗
Sponsor topline filed with SEC / 2026-02-23REDEFINE 4
Obesity with at least one comorbidity
Randomized, open-label, active-controlled; 809 randomized; 84 weeks
- Endpoint
- Mean body-weight change
- Estimand
- Treatment-regimen
Primary non-inferiority endpoint was not achieved. CagriSema investigational in source; detailed safety rates not supplied in reviewed release.
Read the full analysis ↗ WITHIN-TRIAL VIEW / %
Bars show magnitude of reduction; zero at left, 30 % at right. Values retain their negative change signs.
CagriSema 2.4/2.4 mg
-20.2% Original source ↗
Peer-reviewed abstract / 2026-06-07REIMAGINE 2
Type 2 diabetes on metformin ± SGLT2 inhibitor; BMI ≥25
Randomized, double-blind; 2,713 total; primary arms n=603 and n=605; 68 weeks
- Endpoint
- Mean HbA1c change
- Estimand
- Efficacy
Primary HbA1c estimated difference −0.16 points (95% CI −0.27 to −0.05); full paper not reviewed. CagriSema investigational in sponsor record.
Read the full analysis ↗ WITHIN-TRIAL VIEW / percentage points
Bars show magnitude of reduction; zero at left, 2 percentage points at right. Values retain their negative change signs.
CagriSema 2.4/2.4 mg
-1.91 pp Semaglutide 2.4 mg
-1.75 pp Original source ↗
Why this is not a leaderboard
TRIUMPH-1 compares retatrutide with placebo in obesity without diabetes over 80 weeks. REDEFINE 4 compares CagriSema with tirzepatide in obesity over 84 weeks using an open-label design. REIMAGINE 2 asks a primary HbA1c question in type 2 diabetes over 68 weeks. Different populations, comparators, durations and statistical questions prevent a credible cross-trial treatment ranking from these bars.
The missing half of an efficacy chart
Benefit cannot be read without tolerability, discontinuations, serious events, follow-up and applicability. The linked analyses distinguish journal-abstract findings from sponsor-reported adverse events and identify missing safety tables. A positive trial result does not approve an investigational product or establish quality of an outside supplier.
What this selection adds to the year
The annual audit now links original randomized evidence as well as regulatory and registry records. The trial register remains a different object: search returns do not validate trials, and randomized clinical findings do not make the annual archive complete. Download the structured comparison with its source URLs and limits.